TransMedics Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TransMedics Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $605.49M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $441.54M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $241.62M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $93.46M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $30.26M | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | $7.63M | Mar 11, 2021 |
| FY2020 | Sep 30, 2020 | $7.09M | Mar 11, 2021 |
| FY2020 | Jun 30, 2020 | $3.39M | Mar 11, 2021 |
| FY2020 | Mar 31, 2020 | $7.53M | Mar 11, 2021 |
| FY2020 | Dec 28, 2019 | $6.06M | Mar 11, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $31.39M | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | $28.36M | Mar 1, 2022 |
| FY2020 | Dec 28, 2019 | $25.84M | Mar 11, 2021 |
| FY2019 | Dec 29, 2018 | $14.66M | Mar 17, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $362.81M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $262.08M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $154.09M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $65.27M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $21.16M | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | $4.83M | Mar 11, 2021 |
| FY2020 | Sep 30, 2020 | $5.04M | Mar 11, 2021 |
| FY2020 | Jun 30, 2020 | $1.91M | Mar 11, 2021 |
| FY2020 | Mar 31, 2020 | $4.86M | Mar 11, 2021 |
| FY2020 | Dec 28, 2019 | $3.74M | Mar 11, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $190.29M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $35.46M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($25.03M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($36.23M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($44.22M) | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | ($6.31M) | Mar 11, 2021 |
| FY2020 | Sep 30, 2020 | ($5.09M) | Mar 11, 2021 |
| FY2020 | Jun 30, 2020 | ($8.50M) | Mar 11, 2021 |
| FY2020 | Mar 31, 2020 | ($8.85M) | Mar 11, 2021 |
| FY2020 | Dec 28, 2019 | ($9.18M) | Mar 11, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $108.58M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $37.50M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($28.73M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($31.44M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($39.43M) | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | ($5.90M) | Mar 11, 2021 |
| FY2020 | Sep 30, 2020 | ($4.61M) | Mar 11, 2021 |
| FY2020 | Jun 30, 2020 | ($7.86M) | Mar 11, 2021 |
| FY2020 | Mar 31, 2020 | ($8.02M) | Mar 11, 2021 |
| FY2020 | Dec 28, 2019 | ($8.69M) | Mar 11, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.06M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $55.97M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $36.06M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $26.81M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $22.30M | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | $18.83M | Mar 11, 2021 |
| FY2020 | Dec 28, 2019 | $19.87M | Mar 11, 2021 |
| FY2019 | Dec 29, 2018 | $13.66M | Mar 17, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $185.17M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $168.62M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $119.55M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $69.90M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $38.28M | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | $24.19M | Mar 11, 2021 |
| FY2020 | Dec 28, 2019 | $23.60M | Mar 11, 2021 |
| FY2019 | Dec 29, 2018 | $12.32M | Mar 17, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $192.84M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $48.80M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($13.03M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($45.82M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($28.86M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($30.27M) | Feb 27, 2023 |
| FY2020 | Dec 28, 2019 | ($32.29M) | Mar 11, 2021 |
| FY2019 | Dec 29, 2018 | ($25.98M) | Mar 17, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.25M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $129.74M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $151.85M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $11.91M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $3.52M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $455.0K | Feb 27, 2023 |
| FY2020 | Dec 28, 2019 | $165.0K | Mar 11, 2021 |
| FY2019 | Dec 29, 2018 | $418.0K | Mar 17, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.07B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $804.08M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $706.05M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $277.15M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $134.89M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $152.03M | Mar 1, 2022 |
| FY2020 | Dec 28, 2019 | $105.30M | Mar 11, 2021 |
| FY2019 | Dec 29, 2018 | $42.16M | Mar 17, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $595.27M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $575.47M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $568.85M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $89.77M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $67.04M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $48.14M | Mar 1, 2022 |
| FY2020 | Dec 28, 2019 | $50.65M | Mar 11, 2021 |
| FY2019 | Dec 29, 2018 | $47.88M | Mar 17, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $473.10M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $228.60M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $137.20M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $187.38M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $67.85M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $103.89M | Feb 27, 2024 |
| FY2022 | Dec 28, 2019 | $54.65M | Feb 27, 2023 |
| FY2020 | Dec 29, 2018 | ($192.24M) | Mar 11, 2021 |
| FY2019 | Dec 30, 2017 | ($168.72M) | Mar 17, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.55M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $11.55M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $11.99M | Feb 27, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($277.95M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($468.24M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($503.71M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($478.68M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($442.45M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($398.23M) | Mar 1, 2022 |
| FY2020 | Dec 28, 2019 | ($369.48M) | Mar 11, 2021 |
| FY2019 | Dec 29, 2018 | ($335.94M) | Mar 17, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $394.81M | Feb 27, 2024 |
| FY2023 | Dec 31, 2022 | $201.18M | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | $25.58M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $24.58M | Feb 27, 2023 |
| FY2020 | Dec 28, 2019 | $20.09M | Mar 11, 2021 |
| FY2019 | Dec 29, 2018 | $20.24M | Mar 17, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 27, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 27, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 34.27M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 33.62M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 32.67M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 32.14M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 27.79M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 27.18M | Mar 1, 2022 |